One of Greater Cincinnati’s best-funded startups has named a new chief executive officer as it opens a second office on the East Coast.
CinCor Pharma, a Madisonville-based clinical-stage biopharmaceutical company developing treatments for cardio-renal diseases like hypertension, this week announced Marc de Garidel, a member of its board of directors, as CEO, effective July 6. He replaces Dr. Jon Isaacsohn, who will continue his work as CinCor’s chief scientific officer and a member of its board.
The company said de Garidel will be based in Boston where the company recently opened a second office. While CinCor’s Cincinnati operation has six dedicated employees, de Garidel is building leadership and infrastructure on the East Coast.
Prior to joining CinCor’s board May 20, de Garidel served as CEO of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company acquired by Novo Nordisk in August 2020 for $2.1 billion. From 2010-2016, he served as CEO and chairman of Ipsen SA’s board of directors, where he led a transformation of the public European-based company, effecting a three-fold increase in market capitalization.
Isaacsohn, a former MedPace co-founder, co-founded CinCor in 2018 to bring innovation to the cardio-renal disease space. Its lead asset, CIN-107, is in clinical development for the treatment of hypertension and primary aldosteronism, a condition that leads to high blood pressure; its first patient was dosed in October in a Phase 2 study. CinCor said the compound has great potential for patients who cannot achieve blood pressure goals despite taking multiple anti-hypertensive medications.
In a release, de Garidel said CIN-107 has the potential to be “one of the most significant therapeutic advances in decades.” It's estimated as much as 20% of the global population suffers from hypertension, with more than half of those patients in the United States.
“I have been impressed with the team’s commitment to advancing (CIN-107) expeditiously through clinical development,” de Garidel said in the release. “I look forward to working with the executive team to bring (it) to patients who would benefit.”
CinCor ranks eighth on a 2020 Courier list of best-funded startups. CinCor in 2019 completed a $50 million Series A led by California-based Sofinnova Investments, Sofinnova Partners and 5AM Ventures.
